Evidence map›Paper›PMID 22108907›Full record

Trial reportThe international journal of cardiovascular imaging2012

Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.

Salvatore Brugaletta, Josep Gomez-Lara, Hector M Garcia-Garcia, Jung Ho Heo, Vasim Farooq, Robert J van Geuns, Bernard Chevalier, Stephan Windecker, Dougal McClean, Leif Thuesen and 7 more

Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in The international journal of cardiovascular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology.Journal of cardiovascular translational research · 2014
    Review
  8. Cardiovascular imaging 2012 in the International Journal of Cardiovascular Imaging.The international journal of cardiovascular imaging · 2013
    Review
  9. Absorbable stent: focus on clinical applications and benefits.Vascular health and risk management · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 8 countries.

Salvatore BrugalettaDepartment of Interventional Cardiology, Thoraxcenter, Erasmus MC, 's Gravendijkwal 230, 3015, Rotterdam, CE, The Netherlands.
Josep Gomez-Lara
Hector M Garcia-Garcia
Jung Ho Heo
Vasim Farooq
Robert J van Geuns
Bernard Chevalier
Stephan Windecker
Dougal McClean
Leif Thuesen
Robert Whitbourn
Ian Meredith
Cecile Dorange
Susan Veldhof
Richard Rapoza
John A Ormiston
Patrick W Serruys
Erasmus University Rotterdam · NLAbbott (Belgium) · BEAarhus University Hospital · DKAbbott Vascular (United States)Auckland City Hospital · NZCardialysis (Netherlands) · NLErasmus MC · NLInstitut Cardiovasculaire Paris Sud · FRSt Vincent's Hospital Melbourne · AUUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serial intravascular ultrasound virtual histology (IVUS-VH) after implantation of metallic stents has been unable to show any changes in the composition of the scaffolded plaque overtime. The everolimus-eluting ABSORB scaffold potentially allows for the formation of new fibrotic tissue on the scaffolded coronary plaque during bioresorption. We examined the 12 month IVUS-VH changes in composition of the plaque behind the struts (PBS) following the implantation of the ABSORB scaffold. Using IVUS-VH and dedicated software, the composition of the PBS was analyzed in all patients from the ABSORB Cohort B2 trial, who were imaged with a commercially available IVUS-VH console (s5i system, Volcano Corporation, Rancho Cordova, CA, USA), immediately post-ABSORB implantation and at 12 month follow-up. Paired IVUS-VH data, recorded with s5i system, were available in 17 patients (18 lesions). The analysis demonstrated an increase in mean PBS area (2.39 ± 1.85 mm(2) vs. 2.76 ± 1.79 mm(2), P = 0.078) and a reduction in the mean lumen area (6.37 ± 0.90 mm(2) vs. 5.98 ± 0.97 mm(2), P = 0.006). Conversely, a significant decrease of 16 and 30% in necrotic core (NC) and dense calcium (DC) content, respectively, were evident (median % NC from 43.24 to 36.06%, P = 0.016; median % DC from 20.28 to 11.36%, P = 0.002). Serial IVUS-VH analyses of plaque located behind the ABSORB struts at 12-month demonstrated an increase in plaque area with a decrease in its NC and DC content. Larger studies are required to investigate the clinical impact of these findings.

Indexed as

Absorbable ImplantsPlaque, AtheroscleroticTissue ScaffoldsUltrasonography, InterventionalAgedAustraliaCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsEuropeEverolimusFemaleFibrosisHumansMaleCardiovascular AgentsEverolimusSirolimus

Identifiers

PMID22108907
PMCPMC3463791
OpenAlexW2003688632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.